公开(公告)号：EP1984350A1

公开(公告)日：2008-10-29

申请号：EP07716906.8

申请日：2007-01-22

申请人： NOVARTIS AG

发明人： BURGER, Matthew ,  NI, Zhi-jie ,  PECCHI, Sabina ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  FRAZIER, Kelly ,  SMITH, Aaron ,  VERHAGEN, Joelle ,  ZHANG, Yanchen ,  WAGMAN, Allan ,  NG, Simon ,  PFISTER, Keith ,  POON, Daniel ,  LOUIE, Alicia ,  PICK, Teresa ,  BARSANTI, Paul ,  IWANOWICZ, Edwin ,  FANTL, Wendy ,  HENDRICKSON, Thomas ,  KNAPP, Mark ,  MERITT, Hanne ,  VOLIVA, Charles ,  WIESMANN, Marion ,  XIN, Xiahua

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12

摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

公开(公告)号：EP1984350B1

公开(公告)日：2010-08-18

申请号：EP07716906.8

申请日：2007-01-22

申请人： Novartis AG

发明人： BURGER, Matthew ,  NI, Zhi-jie ,  PECCHI, Sabina ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  FRAZIER, Kelly ,  SMITH, Aaron ,  VERHAGEN, Joelle ,  ZHANG, Yanchen ,  WAGMAN, Allan ,  NG, Simon ,  PFISTER, Keith ,  POON, Daniel ,  LOUIE, Alicia ,  PICK, Teresa ,  BARSANTI, Paul ,  IWANOWICZ, Edwin ,  FANTL, Wendy ,  HENDRICKSON, Thomas ,  KNAPP, Mark ,  MERITT, Hanne ,  VOLIVA, Charles ,  WIESMANN, Marion ,  XIN, Xiahua

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12

摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.